Samson for his nimbleness in continuing to proceed with his meeting in a virtual way. Brian Cole from Rush University Medical Center in Chicago. It should be really interesting and something that has really never been done before and we thought why not? In honor of our faculty, we have donated to the San Diego Foundation, which is a non-profit dedicating research a hundred percent towards COVID using cell therapies. We appreciate you taking time away from your family as we are getting back to practice and really emphasizing the importance of doing this together. In many cases, it can be quite difficult. I know it is very challenging and awkward doing a Zoom based lecture and live. Without our sponsors, we could not put on such a production, as well as our faculty.
I want to thank our faculty as well as our sponsors. We need to overcome the challenges and continued widespread use and access not to a select few but to the global community. We have almost a thousand practitioners and attendees tuning in from around the world and are starting to spread the reach of these biologics.
Our ultimate goal here, the big picture ten thousand foot view, as a global community, is widespread patient access to Orthobiologics. And lastly, we are going to be getting more tools from the industry so that we can potentially help our patients. You are going to be hearing about classifications, cell counting and really standardizing our biologics so we know what we are putting in our patients and what is working and what is not. The technologies here, most of us in standard clinical practice can now integrate data registry and collection of outcomes. We need to be integrating massive clinical data. As a group, we need some clarity on which biologics we can and cannot use so we stay within the speed limit and you will be hearing about some of that this week. All too often clinicians are not being included at the table and our voices are not being heard. We need a seat at the table with the government in the FDA. Physicians and industry, we all need to work together to advance this field and promote the credibility that we deserve. They are all marching with the same singular voice. Societies are going to hear a lot about this weekend. So what our goal should be? The theme of inclusivity. We have seen through that time lots of level one studies for knee osteoarthritis as well as for plantar fasciitis that we are going to hear about.
STEM CELL THERAPY RESULTS AT BLUETAIL MEDICAL GROUP TRIAL
Then we had our first TOBI conference in 2010, followed by a level one multicenter trial with many of our colleagues on lateral epicondylitis. I personally published a review article of PRP at the time in 2008, which was then followed by the sensation in the media of a Super Bowl athlete, Hines Ward receiving PRP, which really helped raise awareness, although with the lack of data at the time. Ellen Mishra published a small pilot study on the American Journal of Sports Medicine on PRP, followed by Chris Santino explaining the rationale for bone marrow concentrate in the hip. And then hyaluronic acid came on to the marketplace, followed by a maxillofacial surgeon and Mark, sharing their work with PRP. In 1991, Arnold Caplan coined the term MSC’s. And then at the end of the 80s decade, we had the first patient treated for osteonecrosis of the femoral head by Dr. Ferrari, we learned more about PRP application. Then shortly afterward through cardiothoracic surgery with Dr. And so when we see here, we typically began around the mid-'80s with Philippe Hernigou with the concept of the rationale for cell therapies for osteonecrosis of the femoral head. So, when thinking about Orthobiologics, I was looking at the past four decades in terms of how far we have come yet we are still in our infancy.
0 kommentar(er)
